

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

#5

Application Number	09/870,331
Filing Date	May 30, 2001
First Named Inventor	ZHANG, et al
Group Art Unit	1636
Examiner Name	KATHEE
Attorney Docket Number	ORT-1446

RECEIVED
FEB 15 2002
TECH CENTER 1600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
h	1	ALDEN, K.J., et al. "Differential Effect of Gabapentin on Neuronal and Muscle Calcium Currents", Journal of Pharmacology and Experimental Therapeutics, 2001 Vol. 297:727-735	
	2	ANGELONI, D., et al. "A G-to-A single nucleotide polymorphism in the human Alpha 2 Delta 2 calcium channel subunit gene that maps at chromosome 3p21.3, Molecular and Cellular Probes 2000 Vol. 14:53-54	
	3	BACKONJA, M., et al. "Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus," JAMA 1998 Vol. 280:1831-1836	
	4	BROWN, J.P., et al. "Cloning and Deletion Mutagenesis of the $\alpha 2\delta$ Calcium Channel Subunit from Porcine Cerebral Cortex", Journal of Biological Chemistry 1998 Vol. 273:25458-25465	
	5	BRUHN, T.O., et al. "Activation of Thyrotropin-Releasing Hormone Gene Expression in Cultured Fetal Diencephalic Neurons by Differentiating Agents", 1996 Endocrinology Vol. 137:572-579	
	6	CARBONE, E., et al. "Ca currents in human neuroblastoma IMR32 cells: kinetics, permeability and pharmacology", Pflugers Arch 1990 Vol. 416:170-179	
	7	CLEMENTI, F., et al. "Cell Plasticity During in vitro Differentiation of a Human Neuroblastoma Cell Line", Adv.Exp. Med. Biol. 1991 Vol. 296:91-102	
	8	DISSANAYAKE, V.U.K., et al. "Spermine modulation of specific {3H}-gabapentin binding to the detergent-solubilized porcine cerebral cortex $\alpha 2\delta$ calcium channel subunit" British Journal of Pharmacol. 1997 Vol. 120:833-840	
	9	DOOLEY, D.J., et al. "Inhibition of K ⁺ -evoked glutamate release from rat neocortical and hippocampal slices by gabapentin", Neuroscience Letters 2000 Vol. 280:107-110	
	10	FINK, K., et al. "Inhibition of neuronal Ca ²⁺ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices", British Journal of Pharmacology 2000 Vol. 130:900-906	
	11	GAO, B. et al. "Functional Properties of a New Voltage-dependent Calcium Channel $\alpha 2\delta$ Auxiliary Subunit Gene (CACNA2D2) Journal of Biological Chemistry 2000 Vol. 275:12237-12242	
	12	GEE, N.S., et al. "The Novel Anticonvulsant Drug, Gabapentin (Neurontin) Binds to the $\alpha 2\delta$ Subunit of a Calcium Channel", The Journal of Biological Chemistry 1996 Vol. 271:5768-5776	
	13	GOTTI, C., et al. "Cholinergic receptors, ion channels, neurotransmitter synthesis, and neurite outgrowth are independently regulated during the in vitro differentiation of a human neuroblastoma cell line," Differentiation 1987 Vol. 34:144-155	
N	14	HILL, D.R., et al. "Localization of {3H} gabapentin to a novel site in rat brain: autoradiographic studies", European Journal of Pharmacology, 1993 Molecular Pharmacology Section Vol. 244:303-309	

Examiner Signature	<i>Katherine K. K...</i>	Date Considered	5/16/02
--------------------	--------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DATE
FEB 12 2002

PTO/SB/08A (08 00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

#5

Application Number	09/870,338
Filing Date	May 30, 2001
First Named Inventor	ZHANG, et al
Group Art Unit	1636
Examiner Name	KATHELO
Attorney Docket Number	ORT-1440

RECEIVED
FEB 15 2002
TECH CENTER 600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
✓	15	HOGG, J.E., et al "The human neuroblastoma cell line, IMR-32, expresses functional corticotropin-releasing factor receptors", European Journal of Pharmacology 1996 Vol. 312:257-261	
	16	KURATA, S., et al, "Human neuroblastoma cells produce the NF- κ B like HIV-1 transcription activator during differentiation," Federation of European Biochemical Societies 1993 Vol. 321:201-204	
	17	LAIRD, M. A., et al. "Use of Gabapentin in the Treatment of Neuropathic Pain", The Annals of Pharmacotherapy 2000 Vol. 34:802-807	
	18	MARAI, E., et al. "Calcium Channel α 2 δ Subunits - Structure and Gabapentin Binding", Molecular Pharmacology 2001 Vol. 59:1243-1248	
	19	McENERY, M.W., et al. " β 1B subunit of voltage-dependent Ca ²⁺ channels is predominant isoform expressed in human neuroblastoma cell line IMR32", FEBS letters 1997 Vol. 420:74-78	
	20	ROWBOTHAM, M., et al. "Gabapentin for the Treatment of Postherpetic Neuralgia", JAMA 1998 Vol. 280:1837-1842	
	21	SHISTIK, E., et al. "Ca ²⁺ current enhancement by α 2 δ and β subunits in Xenopus oocytes: contribution of changes in channel gating and α 1 protein level", Journal of Physiology 1995 Vol. 489:55-62	
	22	STEFANI, A., et al. "Gabapentin inhibits calcium currents in isolated rat brain neurons", Neuropharmacology 1998 Vol. 37:83-91	
	23	THURLOW, R.J., et al. "[3H] Gabapentin may label a system-L-like neutral amino acid carrier in brain", European Journal of Pharmacology, 1993 vol. 247:341-345	
	24	THURLOW, R.J., et al. "Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain", British Journal of Pharmacology 1996 Vol. 118:467-465	
	25	WALKER, D., et al. "Subunit interaction sites in voltage-dependent Ca ²⁺ channels: role in channel function", Trends Neuroscience 1998 Vol. 21:148-154	
N	26	WANG, M., et al. "Structural requirement of the calcium channel subunit α 2 δ for gabapentin binding", Biochem J. 1999 vol. 342:513-520	

Examiner's Initials: *Konstantina Katchewski* Date: *5/16/03*

*EXAMINER Initial if reference considered whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached

Applicant is to place a check mark here if the citation is in English. If not, the applicant must provide an English language translation of the citation. The translation must be submitted with the citation and must be a true and accurate translation of the citation.

DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231